Grunau Brian E, Wiens Matthew O, Rowe Brian H, McKay Rachel, Li Jennifer, Yi Tae Won, Stenstrom Robert, Schellenberg R Robert, Grafstein Eric, Scheuermeyer Frank X
St. Paul's Hospital, Vancouver, BC, Canada; Department of Emergency Medicine, University of British Columbia, Vancouver, BC, Canada; School of Population and Public Health, University of British Columbia, Vancouver, BC, Canada; Centre for Health Evaluation and Outcome Sciences, University of Alberta, Edmonton, AB, Canada.
School of Population and Public Health, University of British Columbia, Vancouver, BC, Canada.
Ann Emerg Med. 2015 Oct;66(4):381-9. doi: 10.1016/j.annemergmed.2015.03.003. Epub 2015 Mar 25.
Corticosteroids (steroids) are often used to mitigate symptoms and prevent subsequent reactions in emergency department (ED) patients with allergic reactions, despite a lack of evidence to support their use. We sought to determine the association of steroid administration with improved clinical outcomes.
Adult allergy-related encounters to 2 urban EDs during a 5-year period were identified and classified as "anaphylaxis" or "allergic reaction." Regional and provincial databases identified subsequent ED visits or deaths within a 7-day period. The primary outcome was allergy-related ED revisits in the steroid- and nonsteroid-exposed groups, adjusting for potential confounders with a propensity score analysis; secondary outcomes included the number of clinically important biphasic reactions and deaths.
Two thousand seven hundred one encounters (473 anaphylactic) were included; 48% were treated with steroids. Allergy-related ED revisits occurred in 5.8% and 6.7% of patients treated with and without steroids, respectively (adjusted odds ratio [OR] 0.91; 95% confidence interval [CI] 0.64 to 1.28), with a number needed to treat (NNT) to benefit of 176 (95% CI NNT to benefit 39 to ∞ to NNT to harm 65). The adjusted OR in the anaphylaxis subgroup was 1.12 (95% CI 0.41 to 3.27). In the allergic reaction group, the adjusted OR was 0.91 (95% CI 0.63 to 1.31), with an NNT to benefit of 173 (95% CI NNT to benefit 38 to ∞ to NNT to harm 58). In the steroid and nonsteroid groups, there were 4 and 1 clinically important biphasic reactions, respectively. There were no deaths.
Among ED patients with allergic reactions or anaphylaxis, corticosteroid use was not associated with decreased relapses to additional care within 7 days.
尽管缺乏证据支持,但皮质类固醇(类固醇)常用于缓解急诊科(ED)过敏反应患者的症状并预防后续反应。我们试图确定类固醇给药与改善临床结局之间的关联。
确定了5年期间2个城市急诊科与成人过敏相关的就诊情况,并将其分类为“过敏反应”或“过敏”。地区和省级数据库确定了7天内随后的急诊科就诊或死亡情况。主要结局是类固醇暴露组和非类固醇暴露组中与过敏相关的急诊科复诊情况,采用倾向评分分析调整潜在混杂因素;次要结局包括具有临床意义的双相反应和死亡人数。
纳入了2701例就诊情况(473例过敏反应);48%接受了类固醇治疗。接受和未接受类固醇治疗的患者中,与过敏相关的急诊科复诊率分别为5.8%和6.7%(调整后的优势比[OR]为0.91;95%置信区间[CI]为0.64至1.28),受益所需治疗人数(NNT)为176(95%CI NNT受益为39至无穷大,NNT伤害为65)。过敏反应亚组的调整后OR为1.12(95%CI为0.41至3.27)。在过敏组中,调整后的OR为0.91(95%CI为0.63至1.31),受益所需治疗人数为173(95%CI NNT受益为38至无穷大,NNT伤害为58)。在类固醇组和非类固醇组中,分别有4例和1例具有临床意义的双相反应。无死亡病例。
在急诊科有过敏反应或过敏的患者中,使用皮质类固醇与7天内再次就医的复发率降低无关。